NEW YORK (GenomeWeb News) – Molecular diagnostics developer Trovagene today said that it has closed on a registered direct offering of $15 million of its common stock to an institutional investor at $7 per share.

Separately, the company and RainDance Technologies said earlier in the week that Trovagene has adopted RainDance's RainDrop Digital PCR System for R&D work.

Net proceeds from its $15 million offering will be used for R&D activities, working capital, and general corporate purposes, Trovagene said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.